Non-small lung cancer
Conditions
Interventions
CBDCA + nab-Paclitaxel
Sponsors
Fukuoka University, Facutly of Medicine, Department of Respiratory Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically proven non-small lung cancer 2) Histologically proven malignant effusion 3) Age over 20-years old 4) Performance status (ECOG) = 0-2 5) Never used of anti-cancer treatment except for either kinase treatment or immuno-check point inhibitor 6) Eligible for adjuvant or relapse after surgical treatment 7) Surgical treatment after 6 weeks 8) Adjuvant treatment after one-year 9) Adequate organ functions 10) Patients who have estimated life expectancy longer than 12 weeks 11) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Allergy for either nab-Paclitaxel or Paclitaxel 2) Severe complications such as intersitial pneumonia, CHF, CRF, liver damage, uncontrolled DM or HT 3) Symptomatic brain metastasis 4) Need for dainage 5) History of pleurodesis 6) Surgical treatment within 2 weeks 7) Active infection 8) Active multiple malignancy 9) Uncontrolled mental sympotoms 10) Pregnancy or pregnant possibiltiy 11) Administration of corticosteroids 12) Patients whom doctor consider ineligible
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Control rate for malignant pleural effusion | — |
Secondary
| Measure | Time frame |
|---|---|
| RR, PFS, OS Safety, one-year survival rate Time for increase of pleural effusion Rate of patients who did not require pleurodesis | — |
Countries
Japan
Contacts
Public ContactFumiyasu Igata
Fukuoka University, Facutly of Medicine Department of Respiratory Medicine
Outcome results
None listed